PALO ALTO, Calif. and NEW YORK — September 23, 2026

Evommune, Inc. announced that Phase 2a data for EVO301 in patients with moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna. The presentation will provide detailed results from the Phase 2a proof-of-concept study, building on topline findings reported by the company earlier in 2026. EVO301 is an investigational long-acting interleukin-18 binding protein (IL-18BP) fusion protein designed to neutralize elevated IL-18 activity.

EVO301 Targets Upstream IL-18 Inflammatory Signaling

EVO301 is a long-acting native IL-18BP fused to a serum albumin-binding Fab and is designed to inhibit aberrantly elevated IL-18 signaling. IL-18 is an inflammatory cytokine involved in multiple immune pathways, including Th1, Th2, Th17/22 and innate inflammatory responses. Evommune is developing the approach with the goal of addressing upstream inflammatory signaling that may contribute to the heterogeneous biology of atopic dermatitis. The molecule also incorporates albumin binding intended to extend its half-life and support sustained IL-18 neutralization.

Phase 2a Data to Be Presented at EADV

The late-breaking oral presentation is titled “Positive Top-line Data from the Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL-18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis.” The presentation is scheduled for October 1, 2026, from 4:30 to 4:45 p.m. CEST during the EADV Late Breaking News session. The detailed presentation will provide additional information from the Phase 2a program beyond the topline results previously announced by Evommune.

Advertisement

cGxPJobs Banner

Evommune Plans Phase 2b Dose-Ranging Study

Following the Phase 2a program, Evommune plans to advance EVO301 into a Phase 2b dose-ranging study in moderate-to-severe atopic dermatitis, which the company expects to initiate in mid-2027. EVO301 remains investigational and has not been approved by regulatory authorities for the treatment of atopic dermatitis or other inflammatory diseases. Evommune is also developing a broader pipeline focused on therapies intended to address key biological drivers of chronic inflammatory diseases.

Source :Evommune press release